Impact of comorbid cannabis use on outcome in first episode psychosis.
Comorbid cannabis abuse is common in patients with early psychosis. Little is known about the effect of stopping cannabis use on positive, negative and depressive symptoms. Few studies have controlled for multiple substance use that may mask the specific role that cannabis plays in symptom outcomes. The aim of this study was to investigate whether course and level of cannabis use negatively impacted early psychosis patient symptom profiles (positive, negative and depressive symptoms) over 24 months.



One hundred and ninety-two patients admitted to an early psychosis intervention programme in a naturalistic setting were followed across three time periods: initial presentation, 12 and 24 months. Patients' clinical characteristics (substance use, positive/negative symptoms and depressive symptoms) were assessed at each time period.



There were no significant associations found between cannabis abuse and positive and negative symptoms. Continuation and discontinuation of cannabis use were not significant for cannabis or any other substance when compared to positive and negative symptoms. There was a significant interaction between cannabis and alcohol for depressive symptoms, where depressive symptoms were significantly higher in patients who abused cannabis without co-occurring alcohol abuse when compared to non-cannabis using patients.



The current study findings indicate a complex interaction between cannabis and alcohol use in a sample of early psychosis patients across 24 months. More research is needed into the association between ceasing cannabis use and long-term outcome for early psychosis patients. Of particular importance is the interaction between level of cannabis and alcohol use as it is related to symptom outcome in early psychosis patients.
Department of Psychology, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada.
Kellie L
KL
Hadden
Eastern Health Authority of Newfoundland, Waterford Hospital, PIER Program, St. John's, Newfoundland and Labrador, Canada.|Faculty of Medicine, Memorial University of Newfoundland, Health Sciences Centre, St. John's, Newfoundland and Labrador, Canada.
Kellie
K
LeDrew
Eastern Health Authority of Newfoundland, Waterford Hospital, PIER Program, St. John's, Newfoundland and Labrador, Canada.
Kevin
K
Hogan
Eastern Health Authority of Newfoundland, Waterford Hospital, PIER Program, St. John's, Newfoundland and Labrador, Canada.|School of Pharmacy, Memorial University of Newfoundland, Health Sciences Centre, St. John's, Newfoundland and Labrador, Canada.
Barbara
B
Thomas
D000293:Adolescent; D000328:Adult; D000428:Alcohol Drinking / Q000453:epidemiology*; D002170:Canada / Q000453:epidemiology; D015897:Comorbidity; D003863:Depression / Q000453:epidemiology*; D005260:Female; D006801:Humans; D008297:Male; D008385:Marijuana Smoking / Q000453:epidemiology*; D008875:Middle Aged; D011446:Prospective Studies; D011618:Psychotic Disorders / Q000175:diagnosis / Q000453:epidemiology*; D013997:Time Factors; D055815:Young Adult
alcohol; cannabis; depression; first episode psychosis; schizophrenia